InvestorsHub Logo
Followers 800
Posts 50843
Boards Moderated 1
Alias Born 12/12/2004

Re: None

Tuesday, 12/05/2023 10:27:39 AM

Tuesday, December 05, 2023 10:27:39 AM

Post# of 122
Late November > 424b3 shelf placement > The Prospectus and this prospectus supplement relate to the offer and sale by us of up to (i) 3,220,000 shares of our Class A common stock, par value $0.001 per share (“Class A common stock”), that may be issued upon the exercise of warrants issued on the closing date of our initial public offering to purchase shares of Class A common stock, (ii) 161,000 warrants to purchase shares of our Class A common stock (“Additional Warrants”) that may be issued upon exercise of unit purchase options issued to the underwriters of our initial public offering and (iii) 161,000 shares of our Class A common stock that may be issued upon exercise of the Additional Warrants.

This prospectus supplement should be read in conjunction with the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto, which is to be delivered with this prospectus supplement. This prospectus supplement updates and supplements the information in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common stock is traded on the Nasdaq Capital Market under the symbol “DRCT”. On November 27, 2023, the last reported sale price of our common stock on the Nasdaq Capital Market (“Nasdaq”) was $12.59. Our warrants were traded on Nasdaq under the symbol “DRCTW” until their redemption in full, and subsequent delisting from Nasdaq, on October 30, 2023. There is currently no active trading market for our warrants, nor can there be any assurance that one develops.

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRCT News